<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F00B2D5C-D593-448D-81CF-25F4A56DC57D"><gtr:id>F00B2D5C-D593-448D-81CF-25F4A56DC57D</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Tomlinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/90300D17-7BE0-4E54-B57F-4F4569547B87"><gtr:id>90300D17-7BE0-4E54-B57F-4F4569547B87</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Stewart</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0502165"><gtr:id>23E2D26C-B9C0-4694-A64E-CECF1D83FCDC</gtr:id><gtr:title>Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1: A novel treatment for the Metabolic Syndrome</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502165</gtr:grantReference><gtr:abstractText>The rates of obesity and diabetes are escalating alarmingly in the UK population. These conditions significantly decrease life expectancy and increase the risk of heart attacks and strokes. We believe that increased steroid (cortisol) production within liver and fat tissue is an important cause of these conditions. Studies using newly developed drugs given to rats and mice with diabetes dramatically improve the condition and lower blood glucose levels to those seen in non-diabetic animals. In addition these drugs appear to reduce blood cholesterol levels and decrease weight. In collaboration with Pfizer inc. we now propose to test the efficacy of these drugs in the first human studies. Using a varriety of techniques we will be able to show that these drugs not only inhibit cortisol production form liver and fat, but that they improve blood glucose levels in patients with type 2 diabetes and decrease circulating cholesterol levels.</gtr:abstractText><gtr:technicalSummary>Patients with Cushing?s syndrome inform us of the link between circulating cortisol excess and visceral obesity, type 2 diabetes mellitus and vascular mortality. However, circulating cortisol concentrations are normal in patients with Metabolic Syndrome-Diabetes-Obesity but we have shown that tissue-specific cortisol excess, mediated via 11 beta-hydroxysteroid dehydrogneases (11beta-HSD?s)is implicated in the pathogenesis of hypertension, hepatic glucose output and visceral adipogenesis. 11beta-HSD1, in liver and adipose, acts as an oxo-reductase generating cortisol from inactive cortisone and facilitates glucocorticoid action locally increasing hepatic gluconeogenesis and adipocyte differentiation. Clinical studies have linked 11beta-HSD1 expression to metabolic dysregulation in obesity, diabetes mellitus and polycystic ovary syndrome. Therefore, 11beta-HSD1 inhibition offers a novel therapy to treat patients with the metabolic syndrome by blocking cortisol generation in liver and fat.
In collaboration with Pfizer, we have developed selective 11beta-HSD1 inhibitors, selective in that they inhibit 11beta-HSD1 in human hepatocytes and adipocytes at low nM concentrations (5nM), but not the related 11beta-HSD2 (50 microM). In rodent models of obesity/diabetes they improve insulin sensitivity, reduce blood glucose and body weight.
Clinical studies will define optimal biomarkers of enzyme inhibition. Normal volunteers will be given the non-selective inhibitor carbenoxolone (300mg/day). Urinary cortisol/cortisone metabolites (measured by GC/MS), interconversion of prednisone to prednisolone (HPLC determination), generation of cortisol following oral cortisone acetate, subcutaneous adipose tissue microdialysis (cortisol/cortisone ratios in afferent and efferent catheters) and 11beta-HSD1 expression in adipose tissue biopsies (real-time PCR, primary culture enzyme assays) will be analysed. Studies will then be refined for the investigation of the selective 11beta-HSD1 inhibitor (Pfizer compound 887423). Once effective inhibition of 11beta-HSD1 is confirmed, studies will analyse its effect upon glucose tolerance (OGTT with insulin levels), insulin sensitivity (euglycaemic clamp), hepatic gluconeogenesis (in-house deuterated water assay). Their impact upon fuel metabolism, lipolysis and lipid metabolism will be determined by indirect calorimetry, adipose microdialysis (glycerol release) and adipose biopsy (expression of key enzymes in lipid metabolism). Longer term studies will address their impact upon body composition (DEXA), visceral fat mass (CT quantification) and safety parameters (liver function, biochemistry, haematology, HPA-axis, androgens). 
This hypothesis led research has been fuelled by advances in the laboratory in partnership with Pharma. A translational aspect will potentially deliver a novel therapy for a major health hazard directly for patient benefit. It is likely that a successful outcome of this research will see randomised controlled trials of selective 11beta-HSD1 inhibition in obese patients with and without type 2 diabetes mellitus.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>298509</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Evaluation of selective cortisol inhibitors</gtr:description><gtr:id>991B4EBE-881B-44EF-9EF8-954100A97E70</gtr:id><gtr:impact>Evaluation of novel selective 11hsd1 inhibitors; Phase I and II studies</gtr:impact><gtr:outcomeId>9B59FC702F3-1</gtr:outcomeId><gtr:piContribution>Evaluation of novel selective 11hsd1 inhibitors</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>plenary and symposia lectures</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>781F278C-799E-4320-B1EB-E880CAF5223E</gtr:id><gtr:impact>Large Interntional congresses &amp;gt; 5000 delegates

Press release. Local radio interviews. National press</gtr:impact><gtr:outcomeId>94D739FB8E0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Senior Clinical Fellowship (Jeremy Tomlinson)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>112E6A4E-68DB-43A1-9398-7BACAD530503</gtr:id><gtr:outcomeId>7FF582D39B60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>selective 11BHSD1 inhibitor non clinical use only.</gtr:description><gtr:id>FCBCC42A-6CC0-4310-AA5F-6C1651961733</gtr:id><gtr:impact>Studies published providing efficacy of 11BHSD1 inhibition in man as well as safety and tolerability data</gtr:impact><gtr:outcomeId>4D52D740D4C</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>PF-00915275</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F9B4A021-03C1-411A-B85D-CE882EE62E21</gtr:id><gtr:title>Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe897a89ac5436707fd5b6aef0a3e357"><gtr:id>fe897a89ac5436707fd5b6aef0a3e357</gtr:id><gtr:otherNames>Tomlinson JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>D69C5BCD284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA51A612-F0DF-4E9D-A374-4067F69B587E</gtr:id><gtr:title>Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5d8ef8943d35a20e95fca492fd3713e"><gtr:id>b5d8ef8943d35a20e95fca492fd3713e</gtr:id><gtr:otherNames>Stewart PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>5899ccccb7c184.28270689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E510DC97-4DF3-4C8B-BBF3-CF98091014FE</gtr:id><gtr:title>Steroid production and excretion by the pregnant mouse, particularly in relation to pregnancies with fetuses deficient in Delta7-sterol reductase (Dhcr7), the enzyme associated with Smith-Lemli-Opitz syndrome.</gtr:title><gtr:parentPublicationTitle>The Journal of steroid biochemistry and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/012866744bc3068daaff1ac2fc3d9330"><gtr:id>012866744bc3068daaff1ac2fc3d9330</gtr:id><gtr:otherNames>Matabosch X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0960-0760</gtr:issn><gtr:outcomeId>A3DC5EC0_DA3DC5EC0_D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52652B4D-C466-4EEB-BE69-C044A1595D9F</gtr:id><gtr:title>Male 11?-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74757ba33a4f5d12d4ab5eea50de0695"><gtr:id>74757ba33a4f5d12d4ab5eea50de0695</gtr:id><gtr:otherNames>Larner DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>5899cccc346691.00551550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24A3A567-7C77-4C20-9A44-E0705B909492</gtr:id><gtr:title>High throughput LC-MS/MS method for the simultaneous analysis of multiple vitamin D analytes in serum.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/179964427664d560060191a8a6c31cf4"><gtr:id>179964427664d560060191a8a6c31cf4</gtr:id><gtr:otherNames>Jenkinson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn><gtr:outcomeId>5899cc5ff28a72.05872234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E3937D5-3DB4-435B-854A-21F9200D0803</gtr:id><gtr:title>11?-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88d98bf3954a69fc156c27af9fb0725e"><gtr:id>88d98bf3954a69fc156c27af9fb0725e</gtr:id><gtr:otherNames>Hardy RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>5899ccce1275a6.73528981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABD6EEB8-20D1-45AA-AC96-CD78B15396D6</gtr:id><gtr:title>Modulation of glucocorticoid action and the treatment of type-2 diabetes.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical endocrinology &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe897a89ac5436707fd5b6aef0a3e357"><gtr:id>fe897a89ac5436707fd5b6aef0a3e357</gtr:id><gtr:otherNames>Tomlinson JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1521-690X</gtr:issn><gtr:outcomeId>14CFF79AC12</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D79B0969-2B29-4819-A29F-87007C861D42</gtr:id><gtr:title>Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. Diabetes &amp; endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3371bf5bd214349b10832ad888e2b5a7"><gtr:id>3371bf5bd214349b10832ad888e2b5a7</gtr:id><gtr:otherNames>Clayton RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2213-8587</gtr:issn><gtr:outcomeId>5899cccbaf37b7.12024305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25838E2F-0DE2-4F8B-8094-81E8D9EE9CAF</gtr:id><gtr:title>Acromegaly.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01dc0ed26132145d0eddfb05f09f7965"><gtr:id>01dc0ed26132145d0eddfb05f09f7965</gtr:id><gtr:otherNames>Dineen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>5899cc38528dc8.91468951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BB20668-A460-49FA-9841-F4E24F153B83</gtr:id><gtr:title>Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c094acde392d1809dad156d59cc13759"><gtr:id>c094acde392d1809dad156d59cc13759</gtr:id><gtr:otherNames>Courtney R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>772D7D40737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC958FE9-CF05-425B-ACF7-10FB5A83FFAE</gtr:id><gtr:title>SFRP2 Is Associated with Increased Adiposity and VEGF Expression.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6faad224b0d9f2591b7db726f3b40c7a"><gtr:id>6faad224b0d9f2591b7db726f3b40c7a</gtr:id><gtr:otherNames>Crowley RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5899cccd4ab794.53893970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AF433B5-3D01-4B9B-84E7-2AD68CF7BD1F</gtr:id><gtr:title>Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93a477677cc9edebf839ce62b6b78774"><gtr:id>93a477677cc9edebf839ce62b6b78774</gtr:id><gtr:otherNames>Bhat BG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn><gtr:outcomeId>E0CCC8BEE07</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED3003A7-7BE5-4C64-8A79-609064ADC815</gtr:id><gtr:title>Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/015b14afa6b5b3668d14f53b709742c8"><gtr:id>015b14afa6b5b3668d14f53b709742c8</gtr:id><gtr:otherNames>Weigel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>5899ccce911dd5.94872711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFCD4210-C143-4942-9DE0-BEBEE6C9F701</gtr:id><gtr:title>Glucocorticoids and 11?-HSD1 are major regulators of intramyocellular protein metabolism.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50266dbb5bd134a51e37cc9434e56cf3"><gtr:id>50266dbb5bd134a51e37cc9434e56cf3</gtr:id><gtr:otherNames>Morgan SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>5899cccb289589.72720995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C76A4211-A3A9-4585-881A-949635C808AC</gtr:id><gtr:title>Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe897a89ac5436707fd5b6aef0a3e357"><gtr:id>fe897a89ac5436707fd5b6aef0a3e357</gtr:id><gtr:otherNames>Tomlinson JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>4F23B8217E8</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0502165</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>